Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

PD-1 immune checkpoint blockade promotes brain leukocyte infiltration and diminishes cyst burden in a mouse model of Toxoplasma infection.

Xiao J, Li Y, Yolken RH, Viscidi RP.

J Neuroimmunol. 2018 Jun 15;319:55-62. doi: 10.1016/j.jneuroim.2018.03.013. Epub 2018 Mar 30.

PMID:
29685290
2.

An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study.

Beachler DC, Pinto LA, Kemp TJ, Nyitray AG, Hildesheim A, Viscidi R, Schussler J, Kreimer AR, Giuliano AR.

Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):496-502. doi: 10.1158/1055-9965.EPI-17-0853. Epub 2018 Feb 23.

PMID:
29475967
3.

Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Rossi F, Prosperini L, De Rossi N, Capra R, Rivanera D, Li X, Cinque P, Passeri L, Pozzilli C, Viscidi R.

Viral Immunol. 2017 Oct;30(8):622-626. doi: 10.1089/vim.2017.0039. Epub 2017 Aug 24.

PMID:
28836899
4.

Pre-transplant immune factors may be associated with BK polyomavirus reactivation in kidney transplant recipients.

DeWolfe D, Gandhi J, Mackenzie MR, Broge TA Jr, Bord E, Babwah A, Mandelbrot DA, Pavlakis M, Cardarelli F, Viscidi R, Chandraker A, Tan CS.

PLoS One. 2017 May 31;12(5):e0177339. doi: 10.1371/journal.pone.0177339. eCollection 2017.

5.

Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.

Jiang RT, Wang JW, Peng S, Huang TC, Wang C, Cannella F, Chang YN, Viscidi RP, Best SRA, Hung CF, Roden RBS.

J Virol. 2017 Jul 12;91(15). pii: e00699-17. doi: 10.1128/JVI.00699-17. Print 2017 Aug 1.

6.

Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study.

Pamnani SJ, Sudenga SL, Viscidi R, Rollison DE, Torres BN, Ingles DJ, Abrahamsen M, Villa LL, Lazcano-Ponce E, Salmeron J, Quiterio M, Huang Y, Borenstein A, Giuliano AR.

Cancer Res. 2016 Oct 15;76(20):6066-6075. Epub 2016 Aug 17.

7.

A Difficult Decision: Atypical JC Polyomavirus Encephalopathy in a Kidney Transplant Recipient.

Bialasiewicz S, Hart G, Oliver K, Agnihotri SP, Koralnik IJ, Viscidi R, Nissen MD, Sloots TP, Burke MT, Isbel NM, Burke J.

Transplantation. 2017 Jun;101(6):1461-1467. doi: 10.1097/TP.0000000000001275.

8.

Behavioral Abnormalities in a Mouse Model of Chronic Toxoplasmosis Are Associated with MAG1 Antibody Levels and Cyst Burden.

Xiao J, Li Y, Prandovszky E, Kannan G, Viscidi RP, Pletnikov MV, Yolken RH.

PLoS Negl Trop Dis. 2016 Apr 28;10(4):e0004674. doi: 10.1371/journal.pntd.0004674. eCollection 2016 Apr.

9.

Race is Associated With Sexual Behaviors and Modifies the Effect of Age on Human Papillomavirus Serostatus Among Perimenopausal Women.

Rettig EM, Fakhry C, Rositch AF, Burke AE, Chang K, Silver MI, Viscidi R, Gravitt P.

Sex Transm Dis. 2016 Apr;43(4):231-7. doi: 10.1097/OLQ.0000000000000426.

PMID:
26967299
10.

Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study.

Pierce Campbell CM, Viscidi RP, Torres BN, Lin HY, Fulp W, Abrahamsen M, Lazcano-Ponce E, Villa LL, Kreimer AR, Giuliano AR.

J Infect Dis. 2016 Jul 1;214(1):45-8. doi: 10.1093/infdis/jiw083. Epub 2016 Feb 29.

11.

Central nervous system-specific consequences of simian immunodeficiency virus Gag escape from major histocompatibility complex class I-mediated control.

Beck SE, Queen SE, Viscidi R, Johnson D, Kent SJ, Adams RJ, Tarwater PM, Mankowski JL.

J Neurovirol. 2016 Aug;22(4):498-507. doi: 10.1007/s13365-015-0420-5. Epub 2016 Jan 4.

12.

Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer.

Fakhry C, Qualliotine JR, Zhang Z, Agrawal N, Gaykalova DA, Bishop JA, Subramaniam RM, Koch WM, Chung CH, Eisele DW, Califano J, Viscidi RP.

Cancer Prev Res (Phila). 2016 Feb;9(2):135-41. doi: 10.1158/1940-6207.CAPR-15-0299. Epub 2015 Dec 23.

13.

Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study.

Giuliano AR, Viscidi R, Torres BN, Ingles DJ, Sudenga SL, Villa LL, Baggio ML, Abrahamsen M, Quiterio M, Salmeron J, Lazcano-Ponce E.

Papillomavirus Res. 2015 Dec 1;1:109-115.

14.

BK virus capsid antibodies are associated with protection against subsequent development of PML in HIV-infected patients.

Rossi F, Li X, Jacobson L, Levine AJ, Chen Y, Palella FJ, Margolick J, Viscidi R.

Virology. 2015 Nov;485:467-72. doi: 10.1016/j.virol.2015.08.022. Epub 2015 Sep 7.

15.

Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB.

Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.

16.

A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.

Beachler DC, Viscidi R, Sugar EA, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Reddy S, Gillison ML, D'Souza G.

Sex Transm Dis. 2015 Feb;42(2):93-7. doi: 10.1097/OLQ.0000000000000236.

17.

Patient concerns about human papillomavirus testing and 5-year intervals in routine cervical cancer screening.

Silver MI, Rositch AF, Burke AE, Chang K, Viscidi R, Gravitt PE.

Obstet Gynecol. 2015 Feb;125(2):317-29. doi: 10.1097/AOG.0000000000000638.

18.

BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation.

Satyanarayana G, Hammond SP, Broge TA Jr, Mackenzie MR, Viscidi R, Politikos I, Koralnik IJ, Cutler CS, Ballen K, Boussiotis V, Marty FM, Tan CS.

Transpl Immunol. 2015 Mar;32(2):116-20. doi: 10.1016/j.trim.2014.12.002. Epub 2014 Dec 20.

19.

Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.

Rossi F, Newsome SD, Viscidi R.

Mol Cell Probes. 2015 Feb;29(1):54-62. doi: 10.1016/j.mcp.2014.11.007. Epub 2014 Dec 5. Review.

PMID:
25483260
20.

Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas.

Hampras SS, Viscidi RP, Helzlsouer KJ, Lee JH, Fulp WJ, Giuliano AR, Platz EA, Rollison DE.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2591-6. doi: 10.1158/1055-9965.EPI-14-0370. Epub 2014 Aug 15.

21.

HIV-1, HBV, HCV, HTLV, HPV-16/18, and Treponema pallidum infections in a sample of Brazilian men who have sex with men.

Soares CC, Georg I, Lampe E, Lewis L, Morgado MG, Nicol AF, Pinho AA, Salles RC, Teixeira SL, Vicente AC, Viscidi RP, Gomes SA.

PLoS One. 2014 Aug 1;9(8):e102676. doi: 10.1371/journal.pone.0102676. eCollection 2014.

22.

A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient.

Agnihotri SP, Wuthrich C, Dang X, Nauen D, Karimi R, Viscidi R, Bord E, Batson S, Troncoso J, Koralnik IJ.

Ann Neurol. 2014 Jul;76(1):140-7. doi: 10.1002/ana.24192. Epub 2014 Jun 20.

23.

Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation.

Tan CS, Broge TA Jr, Ngo L, Gheuens S, Viscidi R, Bord E, Rosenblatt J, Wong M, Avigan D, Koralnik IJ.

Biol Blood Marrow Transplant. 2014 Jul;20(7):992-9. doi: 10.1016/j.bbmt.2014.03.018. Epub 2014 Mar 27.

24.

Merkel cell carcinoma arising in inguinal lymph node in a patient with von Willebrand disease after multiple blood transfusions.

Boldorini R, Allegrini S, Tognon M, Miglio U, Rossi D, Pawlita M, Viscidi R.

J Clin Virol. 2014 May;60(1):73-5. doi: 10.1016/j.jcv.2014.02.007. Epub 2014 Feb 24.

PMID:
24630954
25.

Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy.

Brotman RM, Shardell MD, Gajer P, Fadrosh D, Chang K, Silver MI, Viscidi RP, Burke AE, Ravel J, Gravitt PE.

Menopause. 2014 May;21(5):450-8. doi: 10.1097/GME.0b013e3182a4690b.

26.

Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen.

Gomez B, He L, Tsai YC, Wu TC, Viscidi RP, Hung CF.

Cell Biosci. 2013 Jul 15;3(1):29. doi: 10.1186/2045-3701-3-29.

27.

Obesity and human papillomavirus infection in perimenopausal women.

Liu SH, Rositch AF, Viscidi RP, Silver MI, Burke AE, Gravitt PE.

J Infect Dis. 2013 Oct 1;208(7):1071-80. doi: 10.1093/infdis/jit297. Epub 2013 Jul 9.

28.

Detection of JC virus-specific immune responses in a novel humanized mouse model.

Tan CS, Broge TA Jr, Seung E, Vrbanac V, Viscidi R, Gordon J, Tager AM, Koralnik IJ.

PLoS One. 2013 May 20;8(5):e64313. doi: 10.1371/journal.pone.0064313. Print 2013.

29.

Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.

Li J, Ulitzky L, Silberstein E, Taylor DR, Viscidi R.

Viral Immunol. 2013 Apr;26(2):126-32. doi: 10.1089/vim.2012.0076.

30.

Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.

Nicol AF, Grinsztejn B, Friedman RK, Veloso VG, Cunha CB, Georg I, Pilotto JH, Moreira RI, Castro CA, Silver B, Viscidi RP.

J Clin Virol. 2013 Jun;57(2):147-51. doi: 10.1016/j.jcv.2013.02.007. Epub 2013 Mar 9.

PMID:
23490398
31.

Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes.

Kroll JL, Beam C, Li S, Viscidi R, Dighero B, Cho A, Boulware D, Pescovitz M, Weinberg A; Type 1 Diabetes TrialNet Anti CD-20 Study Group.

J Clin Virol. 2013 Jun;57(2):115-9. doi: 10.1016/j.jcv.2013.01.016. Epub 2013 Feb 17.

32.

Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: the Spanish bladder cancer study.

Robles C, Viscidi R, Malats N, Silverman DT, Tardon A, Garcia-Closas R, Serra C, Carrato A, Herranz J, Lloreta J, Rothman N, Real FX, de Sanjose S, Kogevinas M.

Int J Cancer. 2013 Aug 1;133(3):597-603. doi: 10.1002/ijc.28053. Epub 2013 Feb 27.

33.

A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States.

Gravitt PE, Rositch AF, Silver MI, Marks MA, Chang K, Burke AE, Viscidi RP.

J Infect Dis. 2013 Jan 15;207(2):272-80. doi: 10.1093/infdis/jis660. Epub 2012 Dec 12.

34.

The Toxoplasma MAG1 peptides induce sex-based humoral immune response in mice and distinguish active from chronic human infection.

Xiao J, Viscidi RP, Kannan G, Pletnikov MV, Li Y, Severance EG, Yolken RH, Delhaes L.

Microbes Infect. 2013 Jan;15(1):74-83. doi: 10.1016/j.micinf.2012.10.016. Epub 2012 Nov 7.

35.

Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen.

Gomez BP, Wang C, Viscidi RP, Peng S, He L, Wu TC, Hung CF.

Cell Biosci. 2012 Oct 24;2(1):36. doi: 10.1186/2045-3701-2-36.

36.

Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women.

Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE.

Cancer Res. 2012 Dec 1;72(23):6183-90. doi: 10.1158/0008-5472.CAN-12-2635. Epub 2012 Sep 27.

37.

The correlation between human papillomavirus positivity and abnormal cervical cytology result differs by age among perimenopausal women.

Rositch AF, Silver MI, Burke A, Viscidi R, Chang K, Duke CM, Shen W, Gravitt PE.

J Low Genit Tract Dis. 2013 Jan;17(1):38-47. doi: 10.1097/LGT.0b013e3182503402.

38.

Antibody response to Merkel cell polyomavirus associated with incident lymphoma in the Epilymph case-control study in Spain.

Robles C, Poloczek A, Casabonne D, Gonzalez-Barca E, Bosch R, Benavente Y, Viscidi RP, de Sanjosé S.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1592-8. doi: 10.1158/1055-9965.EPI-11-1140. Epub 2012 Jul 10.

39.

Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men.

Lu B, Viscidi RP, Wu Y, Nyitray AG, Villa LL, Lazcano-Ponce E, Carvalho da Silva RJ, Baggio ML, Quiterio M, Salmerón J, Smith DC, Abrahamsen M, Papenfuss M, Giuliano AR.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1542-6. doi: 10.1158/1055-9965.EPI-12-0483. Epub 2012 Jul 3.

40.

Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients.

Pastrana DV, Brennan DC, Cuburu N, Storch GA, Viscidi RP, Randhawa PS, Buck CB.

PLoS Pathog. 2012;8(4):e1002650. doi: 10.1371/journal.ppat.1002650. Epub 2012 Apr 12.

41.

Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Tiggelaar SM, Lin MJ, Viscidi RP, Ji J, Smith JS.

J Adolesc Health. 2012 Feb;50(2):110-31. doi: 10.1016/j.jadohealth.2011.10.010. Review.

42.

Development of a DNA vaccine targeting Merkel cell polyomavirus.

Zeng Q, Gomez BP, Viscidi RP, Peng S, He L, Ma B, Wu TC, Hung CF.

Vaccine. 2012 Feb 8;30(7):1322-9. doi: 10.1016/j.vaccine.2011.12.072. Epub 2011 Dec 29.

43.

Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men.

Lu B, Viscidi RP, Wu Y, Lee JH, Nyitray AG, Villa LL, Lazcano-Ponce E, da Silva RJ, Baggio ML, Quiterio M, Salmeron J, Smith DC, Abrahamsen ME, Papenfuss MR, Stockwell HG, Giuliano AR.

Cancer Res. 2012 Feb 1;72(3):676-85. doi: 10.1158/0008-5472.CAN-11-0751. Epub 2011 Nov 28.

44.

Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women.

Marks MA, Viscidi RP, Chang K, Silver M, Burke A, Howard R, Gravitt PE.

Cytokine. 2011 Dec;56(3):798-803. doi: 10.1016/j.cyto.2011.09.012. Epub 2011 Oct 19.

45.

Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus.

Viscidi RP, Rollison DE, Sondak VK, Silver B, Messina JL, Giuliano AR, Fulp W, Ajidahun A, Rivanera D.

Clin Vaccine Immunol. 2011 Oct;18(10):1737-43. doi: 10.1128/CVI.05175-11. Epub 2011 Aug 31.

46.

JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals.

Viscidi RP, Khanna N, Tan CS, Li X, Jacobson L, Clifford DB, Nath A, Margolick JB, Shah KV, Hirsch HH, Koralnik IJ.

Clin Infect Dis. 2011 Oct;53(7):711-5. doi: 10.1093/cid/cir507. Epub 2011 Aug 18.

47.

A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.

Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, Ghosh A, Morales J, Wacholder S, Guillen D, Alfaro M, Safaeian M, Burk RD, Schiffman M.

J Infect Dis. 2011 Jul 1;204(1):94-102. doi: 10.1093/infdis/jir209.

48.

Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study).

Lu B, Viscidi RP, Lee JH, Wu Y, Villa LL, Lazcano-Ponce E, da Silva RJ, Baggio ML, Quiterio M, Salmerón J, Smith DC, Abrahamsen M, Papenfuss M, Stockwell HG, Giuliano AR.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):990-1002. doi: 10.1158/1055-9965.EPI-10-1160. Epub 2011 Mar 4.

49.

Serological evidence of vertical transmission of JC and BK polyomaviruses in humans.

Boldorini R, Allegrini S, Miglio U, Paganotti A, Cocca N, Zaffaroni M, Riboni F, Monga G, Viscidi R.

J Gen Virol. 2011 May;92(Pt 5):1044-50. doi: 10.1099/vir.0.028571-0. Epub 2011 Feb 9.

PMID:
21307224
50.

No difference in antibody titers against xenotropic MLV related virus in prostate cancer cases and cancer-free controls.

Sabunciyan S, Mandelberg N, Rabkin CS, Yolken R, Viscidi R.

Mol Cell Probes. 2011 Apr-Jun;25(2-3):134-6. doi: 10.1016/j.mcp.2011.01.005. Epub 2011 Jan 31.

Supplemental Content

Loading ...
Support Center